OncoHost Granted New York State Lab Permit, Enabling PROphetNSCLC® Nationwide Access

Original source here

OncoHost Received New York State Laboratory Permit, Expanding Availability of PROphetNSCLC® Precision Oncology Test

On October 22, 2025, OncoHost, a technology company transforming the approach to precision medicine through plasma proteomics and AI, announced that it had received a laboratory permit from the New York State Department of Health Wadsworth Center. This permit enabled the company to offer its PROphetNSCLC® test to physicians and patients across New York State, marking a key milestone in OncoHost’s U.S. expansion.

The New York State Department of Health’s permit reflected the rigorous standards required for clinical laboratory operations and further validated OncoHost’s commitment to quality, accuracy, and compliance.

PROphet®, OncoHost’s AI-powered proteomic profiling platform, was designed to guide first-line treatment decisions in oncology. Its proprietary test, PROphetNSCLC®, had been commercially available since 2023 and supported oncologists treating patients with metastatic non-small cell lung cancer (mNSCLC). Using a single blood sample, the test analyzed thousands of plasma proteins to generate a personalized probability of clinical benefit from PD-1/PD-L1 inhibitors, empowering physicians to optimize treatment selection and improve patient outcomes.

“This permit is a significant step forward in making precision oncology accessible to more patients,” said Ofer Sharon, MD, CEO of OncoHost. “New York State maintains some of the most stringent laboratory certification requirements in the U.S., and meeting these standards underscores our scientific rigor, operational excellence, and dedication to clinical impact.”

The New York permit joins OncoHost’s existing certifications under the Clinical Laboratory Improvement Amendments (CLIA) and its accreditation by the College of American Pathologists (CAP), further strengthening the company’s U.S. testing capabilities and expanding its clinical reach.

“Receiving this permit allows us to serve one of the nation’s largest and most diverse patient populations,” added Amir Gelman, PhD, Director of Laboratory Operations & Assay Development at OncoHost. “We’re proud to deliver reliable, high-quality testing that supports oncologists in making data-driven decisions for their patients.”

‍